Skip to content

FY2027 ICD-10-CM reference

E71.521: Adolescent X-linked adrenoleukodystrophy

By the HCC Buddy Coding Team

The official ICD-10-CM descriptor is Adolescent X-linked adrenoleukodystrophy. The FY2027 annual edition starts October 1, 2026. Check the edition that applies to the encounter or inpatient discharge, including any April update.

Billable code. Verified against the official FY2027 order file.

CMS-HCC V28

No V28 HCC for 2026 dates of service (CMS 2027 Initial ICD-10-CM Mappings)

CMS-HCC V24

Not used for payment year 2027 Medicare Advantage payment

ESRD

  • HCC 23: Other Significant Endocrine and Metabolic Disorders
  • CMS lists the same category for every age band in its model mapping

No RAF is shown: it depends on the member. Mapping: PY2026 CMS mapping; CMS 2027 initial file unchanged.

PACE

Source verification pending

RxHCC

  • HCC 43: Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders

Coefficient pending: payment year 2027 coefficients for this model are not yet verified, so no RAF is shown. Mapping: PY2026 CMS mapping; CMS 2027 initial file unchanged.

HHS-HCC

  • HCC 28: HHS-HCC 28
  • This code has a CMS age requirement: applies when age < 21

No RAF is shown: it depends on the member. Mapping: HHS-HCC 2026 benefit year.

FY2027 Tabular instructions

Instructions below include applicable chapter, section and parent-code notes. Each note identifies where it appears in the official source.

Instructional note

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: E00-E89 (chapter, inherited).

Excludes1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Source: E00-E89 (chapter, inherited).

Excludes1

androgen insensitivity syndrome (E34.5-)

Source: E70-E88 (section, inherited).

Excludes1

congenital adrenal hyperplasia (E25.0)

Source: E70-E88 (section, inherited).

Excludes1

hemolytic anemias attributable to enzyme disorders (D55.-)

Source: E70-E88 (section, inherited).

Excludes1

Marfan syndrome (Q87.4-)

Source: E70-E88 (section, inherited).

Excludes1

5-alpha-reductase deficiency (E29.1)

Source: E70-E88 (section, inherited).

Excludes2

Ehlers-Danlos syndromes (Q79.6-)

Source: E70-E88 (section, inherited).

Excludes1

Schilder's disease (G37.0)

Source: E71.5 (self, inherited).

Source: CMS FY2027 Tabular List and Alphabetic Index.

Open Tabular instructions and code details

Compare the FY2027 additions, removals and billable-status changes

What does E71.521 mean in FY2027?

The official ICD-10-CM descriptor is Adolescent X-linked adrenoleukodystrophy. The FY2027 annual edition starts October 1, 2026. Check the edition that applies to the encounter or inpatient discharge, including any April update.

Is E71.521 billable in FY2027?

The FY2027 order file marks E71.521 as billable. Check the complete Tabular instructions and documentation before assigning it.

Does E71.521 map to an HCC?

E71.521 has no CMS-HCC V28 category in the CMS 2027 Initial ICD-10-CM Mappings (payment year 2027, 2026 dates of service). Under the PY2026 CMS mapping; CMS 2027 initial file unchanged: ESRD HCC 23 (CMS lists the same category for every age band in its model mapping); RxHCC HCC 43. Coefficients for these models are pending verification for payment year 2027. HHS-HCC: HCC 28 (This code has a CMS age requirement: applies when age < 21) under the HHS-HCC 2026 benefit year mapping (no RAF; HHS-HCC weights vary by metal level). CMS-HCC V24: not used for payment year 2027 Medicare Advantage payment (CMS CY 2027 Rate Announcement). The PACE mapping is still pending verification for FY2027.

Source: CMS FY2027 ICD-10-CM order file. Payment model: CMS CY 2027 Rate Announcement. Read the FY2027 Official Guidelines.

Review the FY2026 April edition